Modality
ADC
MOA
Cl18.2
Target
TIGIT
Pathway
Cell Cycle
SchizophreniaADHDThymoma
Development Pipeline
Preclinical
~Nov 2015
→ ~Feb 2017
Phase 1
May 2017
→ Mar 2031
Phase 1Current
NCT05743110
2,312 pts·Thymoma
2022-11→2026-11·Recruiting
NCT04303386
2,629 pts·Schizophrenia
2017-05→2031-03·Not yet recruiting
4,941 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-11-117mo awayInterim· Thymoma
2031-03-165.0y awayInterim· Schizophrenia
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P1
Not yet…
P1
Recruit…
Catalysts
Interim
2026-11-11 · 7mo away
Thymoma
Interim
2031-03-16 · 5.0y away
Schizophrenia
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05743110 | Phase 1 | Thymoma | Recruiting | 2312 | Mayo |
| NCT04303386 | Phase 1 | Schizophrenia | Not yet recr... | 2629 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-8757 | Alnylam | Preclinical | TIGIT | |
| Miritinib | Neurocrine | Phase 3 | TIGIT | |
| UTH-9370 | United Therapeutics | NDA/BLA | TIGIT | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 |